The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Ionis Pharmaceuticals Inc since 2012.
The trader's CIK number is 874015.
At the time of the last reporting, Ionis Pharmaceuticals Inc was the 10% Owner of Akcea Therapeutics, Inc.. (stock ticker symbol AKCA).
Also see all insider trading activities at Akcea Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2015 | RGLS | 0 | $0 | 356,381 | $3,779,156 | 0 | $0 |
| 2012 | RGLS | 750,000 | $3,000,000 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | AKCA | 21,237,715 | $385,464,527 | 0 | $0 | 0 | $0 |
| 2018 | AKCA | 10,666,666 | $199,999,987 | 0 | $0 | 0 | $0 |
| 2017 | AKCA | 3,125,000 | $25,000,000 | 0 | $0 | 0 | $0 |
1. Regulus Therapeutics Inc. (RGLS)
2. Akcea Therapeutics, Inc. (AKCA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2015-07-17 | RGLS | Sale | 111,000 | 10.21 | 1,133,754 |
| 2015-07-16 | RGLS | Sale | 167,000 | 10.79 | 1,801,429 |
| 2015-07-15 | RGLS | Sale | 65,133 | 10.76 | 700,961 |
| 2015-06-30 | RGLS | Sale | 13,248 | 10.79 | 143,012 |
| 2012-10-10 | RGLS | Buy | 750,000 | 4.00 | 3,000,000 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-10-10 | AKCA | Buy | 21,237,715 | 18.15 | 385,464,527 |
| 2018-04-17 | AKCA | Buy | 10,666,666 | 18.75 | 199,999,987 |
| 2017-07-19 | AKCA | Buy | 3,125,000 | 8.00 | 25,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Ionis Pharmaceuticals Inc (10% Owner of Akcea Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.